Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: A systematic review and indirect comparison

Current Medical Research and Opinion

Volumn 28, Issue 4, 2012, Pages 643-650

  Qi, Wei Xiang ^a   Tang, Li Na ^a   He, Ai Na ^a   Shen, Zan ^a   Lin, Feng ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Erlotinib; Maintenance therapy; NSCLC; Pemetrexed; Systematic review

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE;

ADVANCED CANCER; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FATIGUE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84859733908     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.675880     Document Type: Review

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
2. Azzoli CG, Baker Jr S, Temin S, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66
3. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
4. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005;23:2831-9 (Pubitemid 46179474)
5. Williamson SK, Crowley JJ, Lara Jr PN, et al. Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23:9097-104
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8 (Pubitemid 34438899)
7. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-43 (Pubitemid 34182817)
8. Correale P, Miano ST, Remondo C, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +-granulocytemacrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther 2009;8:497-502
9. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol 2011;3:139-57
10. Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncol 2010;6:1827-32
11. Galetta D, Rossi A, Pisconti S,et al. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question. Cancer Treat Rev. 2010;36(Suppl 3):S30-3
12. Zhang X, Zang J, Xu J, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011;140:117-26
13. Cohen MH, Johnson JR, Chattopadhyay S, et al. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010;15:1344-51
14. Cohen MH, Cortazar P, Justice R, et al. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 2010;15:1352-8
15. Muir VJ, Dhillon S. Erlotinib: as maintenance monotherapy in non-small-cell lung cancer. BioDrugs 2011;25:139-46
16. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 2011;14:177-90
17. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23 (Pubitemid 27138611)
18. Gridelli C, Maione P, Rossi A, et al. Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 2011;10:311-17
19. Fuld AD, Dragnev KH, Rigas JR. Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010;11:1387-402
20. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008
21. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13 (Pubitemid 28380142)
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34 (Pubitemid 28562978)
23. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37
24. Bucher HC, Guyatt GH, Griffiths LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91 (Pubitemid 27341818)
25. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multi-centre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9
26. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
27. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009;374:1432-40
28. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010;28(Suppl):15s (abstr 7507)
29. Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):18s (abstr CRA7510)
30. Petrelli F, Borgonovo K, Cabiddu M, et al. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anticancer Drugs 2011;22:1010-19
31. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134
32. Ioannidis JP. Indirect comparisons: the mesh and mess of clinical trials. Lancet 2006;368:1470-2 (Pubitemid 44634678)